Denali Therapeutics Inc. Common Stock
$19.34
USD
Last updated on --.
24h volume1.58M
24h highest19.6110 USD
24h lowest18.4660 USD
24h Price movement+3.78%
DNLI recent prices
24 Hours
+3.78%+$0.705
30 days
-3.01%-$0.601
60 days
+2.64%+$0.48
90 days
-9.72%-$2.081
Key data
Previous close18.6400 USD
Market cap2.99B USD
Volume1.58M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-3.2100 USD
Net income (FY)-508.02M USD
Revenue (FY)--
Last report dateMay 7, 2026
About Denali Therapeutics Inc. Common Stock
HeadquartersSOUTH SAN FRANCISCO
Employees (FY)507.00
Net income per employee (FY)-1.00M USD
Listed onNasdaq
DNLI conversion tables
 |  |
|---|---|
| 0.5 DNLI | 9.672 USD |
| 1 DNLI | 19.34 USD |
| 5 DNLI | 96.72 USD |
| 10 DNLI | 193.45 USD |
| |
|---|---|
| 0.5 USD | 0.025846 DNLI |
| 1 USD | 0.051693 DNLI |
| 5 USD | 0.25846 DNLI |
| 10 USD | 0.51693 DNLI |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
DNLI is trading at $19.34, +3.78% over the last 24 hours. Track live moves on the price chart at the top of this page.
The DNLI stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. DNLI is currently trading at $19.34, +3.78% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on DNLI price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. DNLI's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from DNLI; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against DNLI's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Denali Therapeutics Inc. Common Stock's market cap is currently 2.99B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume1.58M
24h highest19.6110 USD
24h lowest18.4660 USD
24h Price movement+3.78%
Start trade with DNLI Perpetual
Sign up to trade